CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 290 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02390414
NCT02390414N/ACompleted
CompareCT.gov

The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Dana-Farber Cancer Institute·observational·Posted Mar 17, 2015·Updated Apr 3, 2023

In Brief

An observational study for Myelodysplastic Syndromes (MDS). Completed, enrolled 290 participants across 3 sites.

Detailed Summary

The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes (MDS)
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartMay 1, 2011
Primary CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 11.3 years ago